Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195650 · ClinicalTrials.gov registry record · Phase 3
Long Term Open Label Continuation Study
A Phase 3 study of Rheumatoid Arthritis, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 846
- Enrollment target
- 20
- Study locations
NCT00195650 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Abbott. The registered enrollment target is 846 participants, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00195650, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 846 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
Conditions Studied
Interventions
- BIOLOGICAL Adalimumab
Study Locations (20)
California
- Site Reference ID/Investigator# 66822 - Anaheim
- Site Reference ID/Investigator# 557 - La Jolla
- Site Reference ID/Investigator# 387 - Los Angeles
- Site Reference ID/Investigator# 555 - Los Angeles
- Site Reference ID/Investigator# 552 - Santa Barbara
- Site Reference ID/Investigator# 66864 - Santa Monica
- Site Reference ID/Investigator# 535 - Stanford
- Site Reference ID/Investigator# 3412 - Upland
- Site Reference ID/Investigator# 451 - Westlake Village
Alabama
- Site Reference ID/Investigator# 538 - Birmingham
- Site Reference ID/Investigator# 4111 - Birmingham
- Site Reference ID/Investigator# 4113 - Mobile
Colorado
- Site Reference ID/Investigator# 572 - Colorado Springs
- Site Reference ID/Investigator# 4109 - Denver
Connecticut
- Site Reference ID/Investigator# 541 - Danbury
- Site Reference ID/Investigator# 654 - Milford
Alaska
- Site Reference ID/Investigator# 408 - Anchorage
Arizona
- Site Reference ID/Investigator# 537 - Tucson
Delaware
- Site Reference ID/Investigator# 655 - Wilmington
Florida
- Site Reference ID/Investigator# 455 - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 846 participants |
| Start Date | 2000-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195650
The ClinicalTrials.gov registry entry for NCT00195650 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 846 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,686-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (82% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00195650 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT00195650 about?
NCT00195650 is a clinical study titled "Long Term Open Label Continuation Study". The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
What is the current status of trial NCT00195650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 846 participants. The study started on 2000-07. Estimated completion is 2011-05.
What conditions does trial NCT00195650 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00195650?
The interventions under investigation include: Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00195650?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195650 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.